NCT06031805Active, not recruiting
PRostate Olaparib Real World Evidence Study
A French Observational Longitudinal Multicenter Study of Adult Patients Treated in the Real-life Setting With Olaparib for the Treatment of Metastatic Castration Resistant Prostate Cancer
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
This French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 159 (actual)
- First submitted
- 4 Sept 2023
- Start date
- 11 Oct 2023
- Primary completion date
- 13 Oct 2028
- Lead sponsor
- AstraZeneca
- Diseases
- Prostate cancer
- NCT number
- NCT06031805
What you commit to
- Study type: Observational
- Participants enrolled: 159
- From 11 Oct 2023 to the primary completion date, 13 Oct 2028
- 39 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation
Other
- Patients opposed to the collection of their data
Criteria the registry did not label
- Adult male patients (≥ 18 years old)
- with metastatic castration-resistant prostate cancer,
- who have initiated olaparib within at least, the last two months of study entry, at their physician's discretion or who have been enrolled in the funded early access program
- who have been informed and are not opposed to their data collection --- For Patients initiated with olaparib in fEA,
- Still alive and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician);
- who deceased and who did not object to data collection for research purpose(s) during his or her lifetime.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (39)
Sites in registry order. Save your city in your profile to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.